Shots:

• The approval is based on the P-III EMPEROR-Reduced trial evaluating the effect of Jardiance (10 mg- qd) vs PBO in 3730 adults with HFrEF with/out T2D
• The results demonstrated a 25% reduction in the relative risk of the primary composite EPs of time to CV death or hospitalization for HF. The 2EPs demonstrated 30% reduction in the relative risk of first and recurrent hospitalization for HF & safety profile was consistent with the known profile of Jardiance
• In Jun’21- the EC has granted marketing authorization of Jardiance in the EU. The companies continue to investigate the therapy across cardio-renal-metabolic conditions

  | Ref: Eli Lilly | Image:  Eli Lilly